Schizophrenia is a very common psychiatric disorder. However, its etiology and pathogenesis is still unknown. Current theory saying that neurotransmitter imbalance such as serotonin or dopamine only provides limited effectiveness in schizophrenia treatment by drugs changing serotonin and dopamine concentration.
Introduction of these neurotransmitters. Despite of this kind of treatment, the prognosis of schizophrenia is still very poor. Majority of schizophrenic patients are severely disabled in their lifetime. Many of them commit suicide because they cannot tolerate the disease progression. The ineffectiveness of neurotransmitter modification suggests that neurotransmitter imbalance is not the actual cause of schizophrenia.
Among these neurotransmitters, dopamine hypothesis is most widely accepted.
Several researchers suggested that dopamine system in the mesolimbic pathway may contribute the positive symptoms of schizophrenia such as delusion or hallucination.
The excessive dopamine in brain causes the attack of schizophrenia. Certain studies found out that amphetamine and cocaine, two illegal drugs which can lead to schizophrenia symptoms, can increase the brain concentration of dopamine. (Ito 2004; Fox, Esbenshade et al. 2005 ) Thus, it is the reason of amphetamine psychosis and cocaine psychosis. However, these are several defects of the dopamine hypothesis.
Dopamine is a neurotransmitter which is related to motivation. The excessive dopamine may explain the positive symptoms such as hallucination and delusion.
Actually, the excessiveness of dopamine in brain usually causes euphoria, alertness, and over-confidence; these symptoms are more reminiscent of mania than schizophrenia. However, the more detrimental negative symptoms such as avolition (lack of motivation) cannot be explained by the excessive dopamine hypothesis.
Actually, it is the opposite. PET scan was used to study the brain functional dopamine receptors. (Seok Jeong, Kwon et al. 2005 ) When schizophrenia patients have 90% block of dopamine D2 receptors by certain antipsychotic agents, these is little reduction of the psychoses behavior. Furthermore, although dopamine inhibiting medications modify dopamine levels within minutes, the positive symptoms of schizophrenia only subside at least several days or even weeks. In addition, the main target of new generation of antipsychotic agents such as clozapine and quetiapine is not dopamine receptors. They bind and unbind dopamine receptors rapidly in brain. Besides, other psychosis inducing agents such as phencyclidine and ketamine don't have any effect on the brain concentration of dopamine. (Wang, McInnis et al. 2001) Besides the functional anomalies in schizophrenia, there are also anatomical anomalies in schizophrenia such as ventricle enlargement and brain atrophy. (Roberts 1991 ) Dopamine imbalance cannot explain the pathopsysiology of schizophrenia.
However, it is worth noting that dopamine can be secreted by immune cells such as T lymphocytes. Dopamine is a strong immune-mediator suppressing prolactin. Prolactin is usually secreted in late pregnancy to activate Treg cells via STAT5 to suppress maternal immunity. (Gaufo and Diamond 1996; Cosentino, Fietta et al. 2007) Thus, dopamine can suppress the function of regulatory T cells to enhance lymphocyte immunity. This also links the dopamine's work and autoimmunity in schizophrenia.
Serotonin excessiveness is more likely to be related to the positive symptoms of schizophrenia. LSD, an illegal drug which can modulate brain serotonin concentration, can induce visual or auditory hallucination. (Rivero, Sanjuan et al. 2010 Leonard et al. 2001) Actually, these acetylcholine receptors in brain neurons can be the autoantigens for this TH2 autoimmune disease. (Henneberg, Horter et al. 1994; Yang, Chengappa et al. 1994 ) Thus, these TH2 autoimmune cells can attack CNS neurons by recognizing these cortical acetylcholine receptors. Many schizophrenia patients have the sensation of pseudoparasites (delusional parasitosis). They think they have parasite moving in their body such as under the skin. If schizophrenia is a TH2 dominant autoimmune disorder, it can explain this common phenomenon in schizophrenia. TH2 immunological pathway is the host immunity against helminthes parasites. In TH2 immune response, histamine is released by mast cells or basophils to cause the itchiness sensation. Thus, schizophrenic patients will think they are infected by parasites. This kind of "delusion"
suggests that schizophrenia is a TH2 autoimmunity.
Another common symptom in schizophrenia is that patients always feel thirsty and drink a lot of water. This can be explained by histamine. In CNS, histaminergic neurons secreting histamine control the desire of thirst. (Ito 2004 ) Thus, if there are too many histamines in brain, patients will feel extremely thirsty. Histamine is a key effector molecule in TH2 immunity. This phenomenon also suggests that schizophrenia is a TH2 dominant autoimmune illness.
First, schizophrenia patients need to have specific type of HLA to recognize a brain autoantigen such as alpha 7 nicotinic receptor. In addition, accessory molecules play the function like toll-like receptor should be present to trigger TH2 immunological pathway. CNS histaminergic neurons secreting histamine play the key role here.
Many schizophrenia inducing agents such as PCP, amphetamine, or cocaine can induce the release of histamine in CNS. (Prell, Green et al. 1995) Then, histamine can favor this autoimmune to the TH2 immunological pathway. Antihistamine treatment of schizophrenia has been studied and it is functional. (Stevens 1962; Fox, Esbenshade et al. 2005) Histamine receptor allele polymorphism is also related to schizophrenia. (Orange, Heath et al. 1996) As long as the presence of the autoantigen and accessory molecule, the TH2 autoimmunity will persist. Serotonin released from TH2 CD4 T cells, basophils, and mast cells causes hallucination and subsequent delusion. Finally, these TH2 autoantibodies and autoimmune T cells can destroy CNS neurons to cause brain atrophy with ventricle enlargement. Due to the CNS neuron death, the negative symptoms such as avolition, poverty of thought, social withdraw, and speech/behavior disorganization will appear in schizophrenic patients. This TH2 autoimmune hypothesis can well explain the pathophysiology of schizophrenia.
Multiple sclerosis is also a TH2 autoimmune disorder. There are some overlaps between multiple sclerosis and schizophrenia. (Stevens 1988 ) Histaminergic neurons also play important roles in trigger TH2 autoimmunity of multiple sclerosis. However, the major autoantigen in multiple sclerosis is myelin protein. Thus, the major target of autoimmune cells or antibodies in multiple sclerosis is myelin sheath. Neurons are seldom destroyed. Thus, there are infrequent negative symptoms such as avolition or social withdraw in multiple sclerosis. In addition, myelin sheath is more dominant in optic nerves or spinal cord. Thus, optic nerves or spinal cord are first affected in multiple sclerosis. However, in the final stage of multiple sclerosis, TH2 autoimmune cells can also enter CNS and release serotonin to cause symptom such as hallucination. myasthenia gravis is acetylcholine receptors. In my theory, autoantigens in schizophrenia are also nicotinic or muscarinic acetylcholine receptors. Several papers found that anti-cholinergic receptor antibodies are found in schizophrenia patients. (Mukherjee, Mahadik et al. 1994; Borda, Perez Rivera et al. 2002; Chandley, Miller et al. 2009 ) However, the specific type of autoantigen in myasthenia gravis is on the neuromuscular junction. On the contrary, the specific type of acetylcholine receptor in schizophrenia is located in CNS. In addition, myasthenia gravis is a TH9(THαβ) dominant autoimmune disorder not like the TH2 dominance in schizophrenia. Thus, schizophrenia and myasthenia gravis are different diseases.
Because one is TH2 and the other is THαβ, it is very rare that the two diseases appear in one patient concurrently. This is the mutual antagonism suggested by several papers. It is worth noting that thymusmyoid cells bearing AchR are the sources of autoantigens in myasthenia gravis. Thymoma or thymus hyperplasia is usually found in myasthenia gravis. In a PNAS paper, autoantibodies against thymocytes are also noted in serum of schizophrenia patients. (Luria and Domashneva 1974) Thus, the autoantigen of schizophrenia might also be AchR. Ramchand, Wei et al. 1994; Yang, Chengappa et al. 1994 ) Elevated eosinophil cationic protein and eosinophil chemoattractant eotaxin are also noted in schizophrenia. (Hallgren, Venge et al. 1982; Teixeira, Reis et al. 2008) This suggests that schizophrenia is a TH2 dominant immune disease. (Muller, Riedel et al. 2000) In the second criteria, anti-brain antibody transfer into animals such as mice can induce the EEG and behavior change like schizophrenia. In the third criteria, there is a very strong of HLA association with schizophrenia inheritance. This is reported in Nature magazine. (Shi, Levinson et al. 2009; Stefansson, Ophoff et al. 2009 autoimmunity for schizophrenia is unlikely. Retinoic acid, which can prevent eosinophil apoptosis, is also reported to be related to schizophrenia. (Goodman 1995; Goodman 1998; Ueki, Mahemuti et al. 2008) Retinoic acid responsive transcription factor-RORC is also related to TH2 immunity activation (Putheti, Awasthi et al. 2010 ).
Several pathogens are like to the occurrence of schizophrenia. Among these pathogens, toxoplasma gondii is the strongest link. Toxoplasma parasite mainly induces TH2 dominant immune response. Toxoplasma infection can favor a TH2 biased host environment. Thus, it also suggests schizophrenia is a TH2 dominant autoimmune disorder. In the Northern Hemisphere, persons with schizophrenia are more often born in the months from January to April. In the Southern Hemisphere, persons with schizophrenia are more often born in the months from July to September. This could be due to the lowest maternal vitamin D level in these months during pregnancy. (Kinney, Teixeira et al. 2009 ) Vitamin D is a strong TH1 activator and effector. Thus, vitamin D will suppress TH2 immunity. This can explain why birth season affects schizophrenia incidence. The TH1 effector cells are down-regulated in schizophrenia. (Freudenreich, Brockman et al. 2010 ) THαβ(TH9) immunity is also unlikely because of the down-regulation of NK cells and lack of association with IL-10 in schizophrenia. (Abdeljaber, Nair et al. 1994; Sperner-Unterweger, Whitworth et al. 1999; Jun, Pae et al. 2003) The onset of male schizophrenia is from 10 to 25 years old, and the onset of female schizophrenia is from 25 to 35 years old. Schizophrenia will occur after the Treg reduction with the atrophy of thymus during about 10 years old.
The later onset of female schizophrenia can be due to the anti-inflammatory effect of estrogen. Estrogen action delays the onset of schizophrenia in female. DiGeorge syndrome is manifested by thymus atrophy. Thus, Treg production is severely lacking in DiGeorge syndrome. The occurrence of schizophrenia is 100 times higher in DiGeorge syndrome. Schizophrenia is related to lower Treg and IL-2 levels. (Achiron, Noy et al. 1994 ) IL-2 is a cytokine to stimulate regulatory T cells. This implies that schizophrenia is an autoimmune disease. In several clinical studies, anti-inflammatory drugs such as aspirin and NSAIDs can slow down schizophrenia progression (Akhondzadeh, Tabatabaee et al. 2007; Laan, Grobbee et al. 2010) . It also suggests that schizophrenia is an autoimmune disorder.
In addition, many cytokine gene polymorphism is related to the incidence of schizophrenia especially IL-4 and IL-6. (Mittleman, Castellanos et al. 1997 ) IL-6 is found to be up-regulated in CSF and serum of schizophrenia patients. (Akiyama 1999) In addition, IL-2 is down-regulated in CSF and serum of schizophrenia. are also important mediators in TH2 immunity. IL-2 is the main effector of T regulatory cells. Thus, up-regulation of TH2 helper cells and down-regulation of Treg cells can contribute to the occurrence of schizophrenia. Humeral immunity such as complement activation is also reported in schizophrenic patients. (Maes, Delange et al. 1997) Humeral immunity is the manifestation of TH2 immunological pathway. 
